Amyloid Antagonists: The Future of Type 2 Diabetes as Well as Several Neurodegenerative Diseases Treatments

Authors: Mina T Kelleni*

DOI: 10.23880/doij-16000106

Volume 1, Issue 1

Abstract

Type 2 diabetes (T2D) is a growing public health concern that accounts for approximately 90% of all the cases of diabetes. Besides insulin resistance, T2D is characterized by a deficit in beta-cell mass. Increasing evidence points to the cytotoxicity of islet amyloid polypeptide (IAPP) aggregates showing them not just an insignificant phenomenon derived from the disease progression but as agents which directly induce processes that impair the functionality and the viability of beta-cells eventually leading to the loss of beta-cell mass in T2D patients.

Keywords: Type 2 Diabetes; Amyloid Antagonists; Neurodegenerative Diseases

View PDF